Related Experiment Videos
DPP4 inhibitors and cardiovascular outcomes: safety on heart failure
Chang Xia1,2, Aditya Goud2, Jason D'Souza3
1College of Health Science & Nursing, Wuhan Polytechnic University, Wuhan, Hubei, China.
Abstract:
Diabetes is an important risk factor for cardiovascular disease. However, clinical data suggests intensive glycemic control significantly increase rather than decrease cardiovascular mortality, which is largely due to the fact that a majority of oral anti-diabetic drugs have adverse cardiovascular effect. There are several large-scale clinical trials evaluating the cardiovascular safety of DPP4 inhibitors, a novel class of oral anti-diabetic medications, which have been recently completed. They were proven to be safe with regard to cardiovascular outcomes. However, concerns on the safety of heart failure have been raised as the SAVOR-TIMI 53 trial reported a 27% increase in the risk for heart failure hospitalization in diabetic patients treated with DPP4 inhibitor saxagliptin. In this review, we will discuss recent advances in the heart failure effects of DPP4 inhibition and GLP-1 agonism.
Insights
Diabetes increases cardiovascular risk, and while some oral anti-diabetic drugs are unsafe, DPP4 inhibitors show cardiovascular safety. However, heart failure risks with DPP4 inhibitors warrant further investigation.
Area of Science:
- Cardiology
- Endocrinology
- Pharmacology
Background:
- Diabetes mellitus is a significant risk factor for cardiovascular disease (CVD).
- Intensive glycemic control may increase cardiovascular mortality, partly due to adverse effects of oral anti-diabetic drugs.
- Dipeptidyl peptidase-4 (DPP4) inhibitors are a novel class of oral anti-diabetic medications.
Purpose of the Study:
- To review recent advances in understanding the effects of DPP4 inhibition and GLP-1 agonism on heart failure.
- To address concerns regarding the cardiovascular safety of DPP4 inhibitors, particularly heart failure risk.
Main Methods:
- Review of large-scale clinical trials evaluating the cardiovascular safety of DPP4 inhibitors.
- Analysis of data from trials such as SAVOR-TIMI 53 regarding heart failure risk.
- Discussion of recent research on DPP4 inhibition and GLP-1 agonism in relation to heart failure.
Main Results:
- Large-scale trials demonstrate the cardiovascular safety of DPP4 inhibitors regarding overall outcomes.
- The SAVOR-TIMI 53 trial indicated a potential increase in heart failure hospitalization risk with saxagliptin.
- Concerns regarding heart failure safety have been raised for certain DPP4 inhibitors.
Conclusions:
- DPP4 inhibitors are generally safe for cardiovascular outcomes.
- Specific DPP4 inhibitors may be associated with an increased risk of heart failure hospitalization.
- Further research is needed to fully elucidate the heart failure effects of DPP4 inhibition and GLP-1 agonism.